.Attribute Medicine, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin caused strengthened progression-free and total survival, leading to FDA commendation as well as a brand-new therapy possibility for clients.